Tagged: genomics
30 results
Clear Labs
Clear Labs is a San Carlos, California genomics company that builds Clear Dx, a fully automated next-generation sequencing platform. It turns whole genome sequencing - normally a slow, expert-heavy lab process - into a push-button diagnostic used by food manufacturers and public health labs to detect pathogens like Salmonella and Listeria, characterize SARS-CoV-2 and TB, and identify bacteria and fungi from clinical specimens, often with next-day results.
Human Longevity, Inc.
Human Longevity, Inc. is a San Diego- and South San Francisco-based genomics and precision-health company founded in 2013 by genome-sequencing pioneer J. Craig Venter, Peter Diamandis, and Robert Hariri. It pairs clinical-grade whole genome sequencing with whole-body MRI, hundreds of blood biomarkers, and AI analytics - delivered through its Health Nucleus platform - to detect cancer, cardiovascular disease, and other age-related conditions before symptoms appear. After a decade building one of the world's largest longitudinal genotype-phenotype datasets, the company in 2026 launched a $599 clinical-grade whole genome report and spun out Human Life Foundation Models, Inc. to build large-scale AI foundation models for longevity science.
Paragon Genomics
Paragon Genomics is a Fremont, California biotechnology company that makes it faster and cheaper to read the parts of a genome that actually matter. Its patented CleanPlex amplicon sequencing technology turns tiny or degraded DNA and RNA samples into sequencing-ready libraries in a few hours, powering targeted next-generation sequencing for cancer research, infectious-disease surveillance, inherited-disease testing and agricultural genomics. Founded in 2015 and backed by an $8M Series A, the company sells both ready-to-use and custom NGS panels to more than 300 labs worldwide.
Solena
Solena is an agricultural biotechnology company that reads the microbiome of farm soil the way a doctor reads a blood panel. Farmers mail in a soil sample; Solena sequences the DNA of the microbes living in it, scores the soil's biological health with its MISS index, and its Prometheus platform turns that data into AI-driven prescriptions for what to apply, when, and how much. The goal is fewer synthetic inputs, healthier soil, better yields, and eligibility for carbon and regenerative-agriculture incentives.
Niamh O'Hara
Niamh O'Hara is the co-founder and CEO of Biotia, a New York healthtech company that pairs next-generation DNA sequencing with AI to identify pathogens causing hard-to-diagnose infections. An evolutionary biologist by training, she spun the company out of Cornell Tech with Weill Cornell geneticist Christopher Mason, runs a CLIA-certified metagenomics lab in Long Island City, and is building what she calls a global microbial sequence database to catch outbreaks before they spread.
Todd Dickinson
Todd Dickinson is the CEO and a board member of Stellaromics, a Boston biotech commercializing 3D spatial biology born from Karl Deisseroth's Stanford lab and Xiao Wang's work at MIT and the Broad Institute. A Tufts-trained analytical chemist who did his PhD under David Walt, he spent more than 20 years turning genomics inventions into products: over a decade at Illumina during its rise as the DNA-sequencing leader, commercial work on Bionano Genomics' Irys nanochannel arrays, and CEO stints at Dovetail Genomics and Arc Bio, which he merged into Cantata Bio in 2022. At Stellaromics he raised $80 million in Series B (led by Catalyst4 with Stanford University Ventures) to launch Pyxa, the first commercial platform that reads gene expression inside intact tissue up to 40x thicker than conventional methods.
Algorithmic Biologics
Algorithmic Biologics is a Bengaluru- and Delaware-based deep-tech company that treats molecular testing as an information-processing problem. Founded by molecular-computing researcher Dr. Manoj Gopalkrishnan, its patented Tapestry platform uses compressed sensing and combinatorial pooling to run large-scale DNA/RNA/protein tests with far fewer reactions - screening many samples at once and only zooming in where a signal exists. The approach first proved itself as an award-winning, regulator-approved COVID-19 pooling solution and now targets affordable genomics, multiplexed diagnostics, and accelerated assay design.
Fauna Bio
Fauna Bio is an AI-driven drug discovery company that mines roughly 100 million years of evolved disease resistance in mammals to find new human therapies. Founded in 2018 in the San Francisco Bay Area, it combines comparative genomics, a proprietary animal biobank, and machine learning - through its Convergence and Fauna Brain platforms - to translate the biology of hibernators and other resilient species into drug targets for conditions like obesity, heart failure, neurodegeneration, and retinal disease. Its work has attracted a partnership with Eli Lilly worth up to $494 million.
Genomelink
Genomelink is a consumer genomics platform - a self-described 'DNA App Store' - that lets people upload raw DNA data from services like 23andMe, AncestryDNA, and MyHeritage to unlock 400+ trait reports and deep ancestry breakdowns without buying another test kit. Operated by AWAKENS, Inc. and based in Berkeley, California, the company was founded by three genomics specialists from Japan who built it into one of the largest independent DNA-analysis sites while pushing into AI-powered genealogy (YourRoots) and clinical screening (T1D Scout).
Sentieon
Sentieon builds ultra-fast, highly accurate software for analyzing DNA and RNA sequencing data. Its pipelines - DNAseq, DNAscope, TNseq, and TNscope - replace the open-source GATK workflow with matching or better accuracy while running many times faster on ordinary CPUs, no specialized hardware required. Founded in 2014 and based in the Bay Area, the company has won top honors in multiple precisionFDA and DREAM challenges, and its tools are used by pharma, clinical labs, sequencing platform makers, and genomics researchers worldwide to turn raw reads into trustworthy variant calls quickly and cheaply.
James Lu
James Lu is the co-founder and CEO of Helix, a population genomics company he helped launch in 2015 with Justin Kao and Scott Burke. An MD/PhD trained at Baylor College of Medicine with chemical engineering degrees from Stanford, Lu built his career at the intersection of machine learning, electronic health records, and genetics. He argues that the genome should sit alongside blood pressure and cholesterol as a core clinical input - the difference being that your genome never changes. Under his leadership Helix runs one of the largest clinical sequencing labs in the US and the Helix Research Network, and its GenoSphere dataset links more than 500,000 clinico-genomic records.
Jonathan Wang
Jonathan Wang is the co-founder and CEO of Watershed (Watershed Informatics / Watershed Bio), a Cambridge-based biocomputing platform that lets biologists run complex multi-omics analyses without writing code. An MIT computer scientist who once built a high-frequency trading hedge fund out of his dorm room, Wang co-founded Domeyard before pivoting to biology in 2019, applying the speed-obsessed engineering culture of quant finance to the sprawling data problem of modern drug discovery. Watershed raised a $14.5M Series A led by Canvas Ventures in 2023 and aims to become the dominant biocomputing platform for the world's scientists.
Marilyn Matz
Marilyn Matz is the CEO and co-founder of Paradigm4, the Waltham, Massachusetts company behind SciDB, an array-native computational database built for the tangled, multi-dimensional data of genomics, clinical research, and imaging. She launched it in 2010 with database legend and Turing Award laureate Mike Stonebraker to move his MIT research into the hands of working scientists. Decades earlier she left MIT to co-found Cognex, now a global machine-vision powerhouse, where she ran worldwide engineering and later a business unit. A two-time technical founder who codes the deep infrastructure and still sells to the customer, Matz has spent a career making impossibly large scientific data explorable, reproducible, and fast.
Jun Ye
Jun Ye is the co-founder, president and CEO of Sentieon, a Mountain View bioinformatics company whose variant-calling software has swept the precisionFDA Truth and Consistency Challenges. A Stanford-trained electrical engineer with more than 50 U.S. patents, he previously co-founded Brion Technologies (acquired by ASML in 2006) and Founton Technologies (acquired into Alibaba in 2012), and taught at Stanford as a consulting professor for fourteen years.
Arima Genomics
Arima Genomics is a Carlsbad, California biotech commercializing Hi-C technology - sequencing methods that reveal the 3D structure of the genome. Its research kits help scientists assemble chromosome-scale genomes and study chromatin architecture, while its clinical brand Aventa Genomics turns the same proximity-ligation chemistry into FFPE-friendly cancer tests for fusions, rearrangements, and other structural variants conventional NGS often misses.
Adam Margolin
Adam Margolin is a computational biologist turned biotech founder who co-founded Flashpoint Therapeutics, a clinical-stage company engineering spherical-nucleic-acid nanomedicines that aim to turn weak cancer therapies into curative ones. After a 20-year academic career that took him from Wharton and Wall Street to running the #3-ranked genetics department in the country at Mount Sinai, and a stint as a Venture Partner at Khosla Ventures, he teamed with Northwestern nanotech pioneer Chad Mirkin to build Flashpoint. He led the company as founding CEO through a $10M seed round before handing the chief executive role to biotech veteran Barry Labinger in 2025. His mission is deeply personal: his mother died of cancer when he was three.
Ashley Zehnder
Ashley Zehnder is the co-founder and CEO of Fauna Bio, a Berkeley biotech mining the genomes of hibernating ground squirrels, bears and 452 other mammal species for drugs that could treat humans. A boarded avian veterinarian with a Stanford PhD in cancer biology, she had her career epiphany while giving chemotherapy to a parrot, when a faculty member asked in disbelief, 'Birds... get cancer?' That question convinced her the wall between animal and human medicine was an illusion. Fauna Bio's Convergence AI platform turns the survival tricks of extreme mammals into therapeutic targets, work that has drawn partnerships with Eli Lilly and Novo Nordisk and NASA-funded research into putting astronauts into a hibernation-like state.
Clayton Rabideau
Clayton Rabideau is the founder and CEO of Syntensor, a San Francisco startup building foundation models and mechanistic simulations of human cell biology to predict drug efficacy, toxicity, and the hidden causes of clinical-trial failure. A Cambridge PhD in chemical engineering and biotechnology, he works at the seam between dynamical-systems mathematics and genomics - a co-author on HyenaDNA, the NeurIPS 2023 spotlight that stretched genomic language models to a million bases of context. He is trying to make biology as fast, iterative, and programmable as software.
Hiranjith H
Hiranjith H (also Hiranjith GH) is the Chief Business Officer of Algorithmic Biologics, a Bengaluru-founded deeptech startup that embeds algorithms inside test tubes to make molecular testing dramatically cheaper and faster. Based in the San Francisco Bay Area, he leads the company's commercial operations and US expansion. He spent more than a decade scaling MedGenome's research-services business in the US and earlier built commercialization and analytics strategy for life-sciences clients at Novartis, ZS Associates, and Accenture Management Consulting.
Sema Sgaier
Sema Sgaier is the co-founder and CEO of Surgo Health, a Washington, DC public benefit corporation that uses AI and behavioral science to decode the 'why' behind health behaviors. A trained molecular biologist and neuroscientist turned serial entrepreneur, she spent a dozen years at the Bill & Melinda Gates Foundation scaling HIV-prevention programs across India and Africa before co-founding Surgo Foundation, Surgo Ventures, and Surgo Health. She has authored more than 60 peer-reviewed papers, taught at Harvard and the University of Washington, writes op-eds for The New York Times, and is a trained documentary photographer.
OptraHEALTH
OptraHEALTH is a San Jose-based AI healthcare intelligence company that turns dense genomic and clinical data into plain conversation. Its patented HealthFAX platform and GeneFAX product line use conversational AI, natural language processing, and knowledge graphs to help labs, hospitals, payors, and patients navigate genetic testing, revenue cycle management, prior authorization, and clinical decisions - letting people ask their health data questions through chat, mobile, and voice interfaces.
Alex Aravanis
Alex Aravanis is the CEO and co-founder of Moonwalk Biosciences, a precision epigenetics company he launched in 2024 with $57 million and Broad Institute scientist Feng Zhang. An engineer-turned-physician with degrees from UC Berkeley and Stanford, he co-founded the cancer early-detection company GRAIL, later returned to Illumina as Chief Technology Officer, and now wants to rewrite the 'software of the genome' without cutting a single strand of DNA.
Citizen Health
Citizen Health is a San Francisco-based AI health platform built for people living with rare and complex conditions. It pulls a patient's fragmented medical records into one place, turns them into a structured, queryable dataset, and layers on an AI advocate plus a peer community so patients, families, and clinicians can ask plain-language questions and find the next best step. Consenting patient data also powers research for pharmaceutical partners. The company grew out of Ciitizen, the patient-data startup acquired by Invitae, and relaunched independently in December 2023.
ConcertAI
ConcertAI is a Cambridge, Massachusetts company that combines real-world clinical, genomic, imaging, and claims data with applied AI to accelerate cancer research and clinical development. Through its CARA AI platform, large independent oncology data network, and Digital Trial Solutions, it helps biopharma companies, healthcare providers, and medical societies design smarter trials, match patients faster, and generate evidence on how treatments perform outside controlled studies.
Hexagon Bio
Hexagon Bio is a Menlo Park biotech that mines the genomes of fungi and other microbes to discover new medicines. Its platform pairs machine learning, genomics, and synthetic biology to read DNA sequences, predict the small molecules they encode, and connect those molecules to the human proteins they act on - skipping the random trial-and-error that has long defined natural-product drug discovery. The company is focused on novel cytotoxic payloads for antibody-drug conjugates (ADCs) in oncology, and in late 2025 extended its approach to agriculture through a joint venture with Corteva.
LatchBio
LatchBio is a San Francisco company building an AI-native data platform for biology. It lets scientists store, analyze, and visualize data from 40+ lab kits and instruments without writing code or managing cloud infrastructure - turning raw sequencing and experimental output into reproducible, publication-ready results. Founded in 2021 by three Berkeley dropouts, it now serves thousands of scientists at biopharmas and research labs and is positioning itself as 'the AI agent for biology data analysis.'
Alfredo Andere
Alfredo Andere is the co-founder and CEO of LatchBio, a San Francisco company building cloud and machine-learning infrastructure for biology. Born in Mexico City and raised in Guadalajara, he studied Electrical Engineering and Computer Science at UC Berkeley, worked at Google on the TensorFlow-NumPy framework and as a data engineer at Facebook, then dropped out of Berkeley in early 2021 with two college friends to start LatchBio. The trio conducted roughly 300 customer interviews before writing code, raised an oversubscribed $5M seed led by Lux Capital, and have since scaled the company through a $28M Series A and a 2026 Series B, bringing total funding to $163M. Andere is a Forbes 30 Under 30 honoree.
Alice Zhang
Alice Zhang is the CEO and co-founder of Verge Genomics (now Verge Labs), a San Francisco biotech she started in 2015 after walking away from an MD/PhD program at UCLA. She built a company that pairs machine learning with one of the largest collections of human brain tissue to find drug targets for diseases like ALS, Parkinson's and Alzheimer's. A Princeton molecular biology graduate, Soros Fellow and Forbes 30 Under 30 honoree, Zhang turned her inexperience into what she calls a 'superpower,' raising more than $130 million and partnering with Eli Lilly and AstraZeneca before pivoting the company toward selling its data and insights to pharma in 2025.
NuCicer
NuCicer is a Davis, California agtech and food-tech company breeding a new generation of high-protein chickpeas. Spun out of UC Davis and built on the largest pool of chickpea genetic diversity on earth, the company uses predictive (precision) breeding and genomics to develop chickpea varieties with up to 75% more protein than conventional beans - alongside better flavor, lower fat, and higher fiber. NuCicer sells whole beans, functional flours, protein powders, and bespoke trait packages to food brands seeking minimally processed, sustainable plant-protein ingredients that out-compete soy and pea isolates on taste and texture.
Nucleus Genomics
Nucleus Genomics is a New York-based consumer genomics company that sells a $399 at-home, clinical-grade whole-genome sequencing kit and a software platform that turns a person's full DNA sequence into readable reports on disease risk, carrier status, traits, and longevity. Founded in 2021 by Thiel Fellow Kian Sadeghi, Nucleus pairs whole-genome data with polygenic risk scores and lifestyle inputs to estimate risk for common, complex conditions. In 2025 it expanded into reproductive products - carrier screening, partner DNA alignment, and a controversial embryo-ranking tool, Nucleus Embryo - that put the company at the center of a public debate over the science and ethics of genetic selection.